Pancreatitis Perspective

 
 
  • 11 More Highlights From Digestive Disease Week 2023   Dr David Johnson offers yet more practice-changing observations from this year's meeting, which featured an abundance of data on novel treatments and new revelations about established interventions.
  • DDW 2023 Read clinically focused news coverage of key developments from DDW 2023.
  • Is It Time to Stop Treating High Triglycerides? Trials showing little effect of triglyceride-lowering drugs on cardiovascular outcomes raise the question of whether it's even worth measuring this lipid, writes cardiologist Chris Labos, MD.
  • What Happens When Newer Weight Loss Meds Are Stopped? Anti-obesity meds are a "game-changer" for many people with obesity, but what happens when people stop taking them? Dr Jaime Almandoz explains.
  • 2022's Top 10 Gastroenterology Publications This year's finest offerings were headlined by key practice guidelines from ACG and AGA, according to Dr David Johnson.
  • The New Obesity Breakthrough Drugs I'm not using the term breakthrough lightly.
  • Highlights in Obesity From ACG 2022   Key updates in obesity management from ACG 2022 include risk factors for acute pancreatitis in patients taking GLP-1 receptor agonists and management of NAFLD, as reported by Dr Carolyn Newberry.
  • Rethinking Fluid Resuscitation in Acute Pancreatitis   Dr David Johnson comments on a new study that has upended our notions of how best to treat acute pancreatitis.
  • State of the Art in NAFLD/NASH Identification and Management   Drs Seth Baum and Jay Shubrook explore the highly anticipated Clinical Care Pathway for the screening, diagnosis, and treatment of NAFLD/NASH.
  • Do Lipid Labs Need to Be Fasting? Experts discuss whether patients need to fast before having their lipids tested.
  • 13 Tips for Pancreatic Cyst Surveillance It can be mystifying sorting through various guidelines on pancreatic cysts and cystic neoplasms. A new review article provides clarity.
  • DDW 2022 10 Highlights From Digestive Disease Week 2022   With a focus on newly approved treatments and those seemingly on the verge, this year's meeting had clear practice-changing implications, says Dr David Johnson.
  • Eliminating Central Line–Associated Bloodstream Infections Central line–associated bloodstream infections (CLABSIs) are a seemingly intractable problem, and reporting requirements complicate the situation. How can a hospital's medical staff respond to this challenge?
  • DDW 2022 Read clinically focused news coverage of key developments from DDW 2022
  • GI Involvement May Signal Risk for MIS-C After COVID Dr William Balistreri comments on data linking gastrointestinal symptoms to this life-threatening complication, and COVID vaccines' efficacy at preventing it.
  • Malpractice Case: How Did Physicians Miss This Abscess? A missed infection triggers a legal claim. Could doctors have diagnosed the problem earlier?
  • 2018 AHA/ACC Multisociety Cholesterol Guideline vs 2019 ESC/EAS Dyslipidemia Guidelines The updated AHA/ACC guideline refined the secondary prevention category and expanded primary prevention to all age groups. Here are five notable comparisons between the AHA/ACC and ESC/EAS guidelines.
  • All About Wegovy for Weight Loss   Anne Peters talks about the newly approved semaglutide (Wegovy) for weight loss -- the various trials, indications and warnings, dosing, and expectations.
  • DDW 2021 Read clinically focused news coverage of key developments from DDW 2021
  • Appendectomy or Antibiotics for Acute Appendicitis?   Drs Robert Glatter, Joseph Sakran, and Ali Raja discuss data related to the use of surgical appendectomy vs antibiotics for acute appendicitis.